Aerosol Medication Use in COVID-19 Pandemic

Musa Topel
Kurtuluş Aksu


Administration of aerolized drugs to patients diagnosed with COVID-19 leads to the risk of transmission of patient-generated infectious aerosols to healthcare providers.While the COVID-19 pandemic is ongoing, in order to provide the best treatment for patients and at the same time to protect healthcare providers at the highest level, it is necessary to increase access to information and pay maximum attention to preventive measures.


Aerosolized medications, bioaerosols, COVID-19
Tüm hakları saklıdır. © 2016 AAI